37 reports of this reaction
1.9% of all CHLORPROMAZINE HYDROCHLORIDE reports
#6 most reported adverse reaction
NEUROLEPTIC MALIGNANT SYNDROME is the #6 most commonly reported adverse reaction for CHLORPROMAZINE HYDROCHLORIDE, manufactured by Advagen Pharma Ltd. There are 37 FDA adverse event reports linking CHLORPROMAZINE HYDROCHLORIDE to NEUROLEPTIC MALIGNANT SYNDROME. This represents approximately 1.9% of all 1,986 adverse event reports for this drug.
Patients taking CHLORPROMAZINE HYDROCHLORIDE who experience neuroleptic malignant syndrome should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
NEUROLEPTIC MALIGNANT SYNDROME is a less commonly reported adverse event for CHLORPROMAZINE HYDROCHLORIDE, but still significant enough to appear in the safety profile.
In addition to neuroleptic malignant syndrome, the following adverse reactions have been reported for CHLORPROMAZINE HYDROCHLORIDE:
The following drugs have also been linked to neuroleptic malignant syndrome in FDA adverse event reports:
NEUROLEPTIC MALIGNANT SYNDROME has been reported as an adverse event in 37 FDA reports for CHLORPROMAZINE HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
NEUROLEPTIC MALIGNANT SYNDROME accounts for approximately 1.9% of all adverse event reports for CHLORPROMAZINE HYDROCHLORIDE, making it a notable side effect.
If you experience neuroleptic malignant syndrome while taking CHLORPROMAZINE HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.